Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.50 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.50 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.50 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ACP3 | P15309 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5139180 | 1.00 | ANPEP (0.50) | ANPEPERAP1ERAP2METAP2METAP1 | |
| SCHEMBL5170558 | 1.00 | ANPEP (0.50) | ANPEPERAP1ERAP2METAP2METAP1 | |
| SCHEMBL8761563 | 0.83 | ANPEP (0.53) | ANPEPERAP1ERAP2METAP2METAP1 | |
| SCHEMBL7993184 | 0.83 | TDP1 (0.44) | ANPEPERAP1ERAP2MAOBMAOA | |
| SCHEMBL30146557 | 0.83 | TDP1 (0.52) | ANPEPERAP1ERAP2MAOBMAOA | |
| SCHEMBL30146580 | 0.83 | TDP1 (0.52) | ANPEPERAP1ERAP2MAOBMAOA | |
| SCHEMBL7268763 | 0.83 | TDP1 (0.52) | ANPEPERAP1ERAP2MAOBMAOA | |
| Hydrochloric Acid SCHEMBL9848355 | 0.81 | MAOB (0.50) | ANPEPERAP1ERAP2MAOBMAOA | |
| SCHEMBL14159706 | 0.80 | ANPEP (0.50) | ANPEPERAP1ERAP2MAOACYP2A6 | |
| SCHEMBL10495575 | 0.80 | ANPEP (0.42) | ANPEPERAP1ERAP2MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210603-A1 | NOVEL SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | TUNG ROGER D | 2010-08-19 | — | — | US | disclosed |
| US-7608632-B2 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-27 | — | — | US | disclosed |
| US-20080293727-A1 | Novel sulfonamide inhibitors of aspartyl protease | TUNG ROGER D | 2008-11-27 | — | — | US | disclosed |
| US-20020052399-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | VAZQUEZ MICHAEL L (US) | 2002-05-02 | — | — | US | disclosed |
| EP-0735019-B1 | Retroviral protease inhibitors | MONSANTO CO (US) | 2000-09-20 | — | — | EP | disclosed |
| US-5843946-A | α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1998-12-01 | — | — | US | disclosed |
| EP-0656887-B1 | HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 1998-10-28 | — | — | EP | disclosed |
| US-5783701-A | ANTI-HIV VIRICIDES | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1998-07-21 | — | — | US | disclosed |
| EP-0804428-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5463104-A | Treating human immunodeficiency virus infection | G. D. SEARLE & CO. (US) | 1995-10-31 | — | — | US | disclosed |
| EP-0656888-A1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-06-14 | — | — | EP | disclosed |
| WO-1994010134-A1 | HYDROXYETHYLAMINO SULFAMIC ACID DERIVATIVES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1994-05-11 | — | — | WO | disclosed |
| WO-1994004493-A1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1994-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052399-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | ANPEP 4/4885ERAP1 11/4885ERAP2 48/4885 |
| US-20100210603-A1 | NOVEL SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | SPINT2, PRSS1, DNPEP | ANPEP 24/4885ERAP1 40/4885ERAP2 44/4885 |
| US-20080293727-A1 | Novel sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | ANPEP 24/4885ERAP1 40/4885ERAP2 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.